{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:42:41Z","timestamp":1760913761233,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"],"award-info":[{"award-number":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"],"award-info":[{"award-number":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"],"award-info":[{"award-number":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007395","name":"Instituto Nacional de Ci\u00eancia e Tecnologia para Excitotoxicidade e Neuroprote\u00e7\u00e3o","doi-asserted-by":"publisher","award":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"],"award-info":[{"award-number":["UID\/Multi\/04462\/2013","CEECIND\/02001\/2017","RECI\/QEQ-MED\/0330\/2012","UID\/QUI\/00100\/2013","SFRH\/BD\/92191\/2013","UID\/DTP\/04138\/2019","UID\/QUI\/00100\/2019","PTDC\/MED-TOX\/29183\/2017","EXPL\/DTP-FTO\/0204\/2012"]}],"id":[{"id":"10.13039\/501100007395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.phrs.2021.105446","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:47:11Z","timestamp":1611748031000},"page":"105446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-9455","authenticated-orcid":false,"given":"Aline T.","family":"Marinho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana R.","family":"Batuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana P.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umbelina","family":"Caixas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara G.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6977-9361","authenticated-orcid":false,"given":"Karina","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-7856","authenticated-orcid":false,"given":"Pedro","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Bourbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Matilde","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra M.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Em\u00edlia C.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-9995","authenticated-orcid":false,"given":"Sofia A.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"February","key":"10.1016\/j.phrs.2021.105446_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","article-title":"Present therapeutic role of cholesteryl ester transfer protein inhibitors","volume":"128","author":"Ferri","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105446_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/vhrm.1.2.119.64083","article-title":"Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium","volume":"1","author":"Norata","year":"2005","journal-title":"VHRM"},{"issue":"March (7)","key":"10.1016\/j.phrs.2021.105446_bib0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1440-1681.2010.05380.x","article-title":"Anti-oxidant properties of high-density lipoprotein and atherosclerosis: HDL: composition and anti-oxidant activity","volume":"37","author":"Podrez","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"August (8)","key":"10.1016\/j.phrs.2021.105446_bib0020","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0022-2275(20)31582-0","article-title":"A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids","volume":"42","author":"Navab","year":"2001","journal-title":"J. Lipid Res."},{"issue":"May (5)","key":"10.1016\/j.phrs.2021.105446_bib0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/bcp.13198","article-title":"Extended\u2010release niacin increases anti\u2010apolipoprotein A\u2010I antibodies that block the antioxidant effect of high\u2010density lipoprotein\u2013cholesterol: the EXPLORE clinical trial","volume":"83","author":"Batuca","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"November (1)","key":"10.1016\/j.phrs.2021.105446_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/ken397","article-title":"Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus","volume":"48","author":"Batuca","year":"2008","journal-title":"Rheumatology"},{"issue":"July (3)","key":"10.1016\/j.phrs.2021.105446_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"December (24)","key":"10.1016\/j.phrs.2021.105446_bib0040","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"December (25)","key":"10.1016\/j.phrs.2021.105446_bib0045","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of Anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"November (22)","key":"10.1016\/j.phrs.2021.105446_bib0050","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of Dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"May (20)","key":"10.1016\/j.phrs.2021.105446_bib0055","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"June (06)","key":"10.1016\/j.phrs.2021.105446_bib0060","first-page":"1088","article-title":"Antibodies against HDL components in ischaemic stroke and coronary artery disease","volume":"118","author":"Batuca","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"February (4)","key":"10.1016\/j.phrs.2021.105446_bib0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/eurheartj\/ehq521","article-title":"Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability","volume":"32","author":"Montecucco","year":"2011","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.phrs.2021.105446_bib0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1160\/TH16-03-0248","article-title":"Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population: results from the CoLaus study","volume":"116","author":"Antiochos","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"June (22)","key":"10.1016\/j.phrs.2021.105446_bib0075","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"issue":"November (17)","key":"10.1016\/j.phrs.2021.105446_bib0080","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0000000000001642","article-title":"Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro","volume":"31","author":"Angelovich","year":"2017","journal-title":"AIDS"},{"issue":"April (4)","key":"10.1016\/j.phrs.2021.105446_bib0085","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jac\/dkq507","article-title":"Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens","volume":"66","author":"Maggi","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"September (13)","key":"10.1016\/j.phrs.2021.105446_bib0090","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jbiomech.2016.05.018","article-title":"Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia","volume":"49","author":"Gleason","year":"2016","journal-title":"J. Biomech."},{"issue":"July (1)","key":"10.1016\/j.phrs.2021.105446_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1086\/518248","article-title":"Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV\u20101\u2013uninfected newborns: the stopping infection from mother\u2010to\u2010child via breast\u2010feeding in Africa Lipid Substudy","volume":"196","author":"Sankatsing","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"September (9)","key":"10.1016\/j.phrs.2021.105446_bib0100","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/ATVBAHA.109.192088","article-title":"Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production","volume":"29","author":"Franssen","year":"2009","journal-title":"ATVB"},{"issue":"January (1)","key":"10.1016\/j.phrs.2021.105446_bib0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/03602532.2019.1577891","article-title":"Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity","volume":"51","author":"Marinho","year":"2019","journal-title":"Drug Metab. Rev."},{"issue":"22","key":"10.1016\/j.phrs.2021.105446_bib0110","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1039\/c1ob06052j","article-title":"Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine","volume":"9","author":"Antunes","year":"2011","journal-title":"Org. Biomol. Chem."},{"issue":"March (3)","key":"10.1016\/j.phrs.2021.105446_bib0115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00204-016-1792-x","article-title":"Hepatocyte spheroids as a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study","volume":"91","author":"Pinheiro","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"February (2)","key":"10.1016\/j.phrs.2021.105446_bib0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jac\/dkt359","article-title":"Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions","volume":"69","author":"Marinho","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"June (1)","key":"10.1016\/j.phrs.2021.105446_bib0125","first-page":"72","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers","volume":"320","author":"Faucette","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"August (8)","key":"10.1016\/j.phrs.2021.105446_bib0130","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1194\/jlr.M700374-JLR200","article-title":"Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice","volume":"49","author":"Masson","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2021.105446_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2013.00002","article-title":"Molecular interactions between NAFLD and xenobiotic metabolism","author":"Naik","year":"2013","journal-title":"Front. Genet."},{"year":"2016","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","key":"10.1016\/j.phrs.2021.105446_bib0140"},{"issue":"May (5)","key":"10.1016\/j.phrs.2021.105446_bib0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2006.02619.x","article-title":"Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients","volume":"61","author":"Pereira","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"December (6)","key":"10.1016\/j.phrs.2021.105446_bib0150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1365-2125.2009.03535.x","article-title":"Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients","volume":"68","author":"Pereira","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"July (7)","key":"10.1016\/j.phrs.2021.105446_bib0155","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/tx8000972","article-title":"Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine","volume":"21","author":"Antunes","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105446_bib0160","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1039\/c3ay41911h","article-title":"Development and validation of an HPLC-UV method for quantifying nevirapine and its main phase I metabolites in human blood","volume":"6","author":"Marinho","year":"2014","journal-title":"Anal. Methods"},{"issue":"November","key":"10.1016\/j.phrs.2021.105446_bib0165","doi-asserted-by":"crossref","first-page":"19682","DOI":"10.7448\/IAS.17.4.19682","article-title":"Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection","volume":"17","author":"Dias","year":"2014","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.phrs.2021.105446_bib0170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1039\/C3AY41527A","article-title":"Quantification of the arylesterase activity of paraoxonase-1 in human blood","volume":"6","author":"Dias","year":"2014","journal-title":"Anal. Methods"},{"issue":"June (2)","key":"10.1016\/j.phrs.2021.105446_bib0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/ten.tec.2008.0352","article-title":"Towards an extended functional hepatocyte in vitro culture","volume":"15","author":"Miranda","year":"2009","journal-title":"Tissue Eng. Part C Methods"},{"issue":"January","key":"10.1016\/j.phrs.2021.105446_bib0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2015.11.019","article-title":"Nevirapine modulation of paraoxonase-1 in the liver: an in vitro three-model approach","volume":"82","author":"Marinho","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"May (19)","key":"10.1016\/j.phrs.2021.105446_bib0185","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2174\/1568026616666160216155043","article-title":"The importance of bioactivation in computer-guided drug repositioning. Why the parent drug is not always enough","volume":"16","author":"Talevi","year":"2016","journal-title":"CTMC"},{"issue":"January (1)","key":"10.1016\/j.phrs.2021.105446_bib0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"January (1)","key":"10.1016\/j.phrs.2021.105446_bib0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1194\/jlr.M057943","article-title":"Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach","volume":"57","author":"Gadkar","year":"2016","journal-title":"J. Lipid Res."},{"issue":"July (7)","key":"10.1016\/j.phrs.2021.105446_bib0200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/labinvest.2016.56","article-title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease","volume":"96","author":"Chistiakov","year":"2016","journal-title":"Lab. Investig."},{"issue":"January (2)","key":"10.1016\/j.phrs.2021.105446_bib0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nm.3459","article-title":"An abundant dysfunctional apolipoprotein A1 in human atheroma","volume":"20","author":"Huang","year":"2014","journal-title":"Nat. Med."},{"issue":"December (12)","key":"10.1016\/j.phrs.2021.105446_bib0210","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.bbadis.2013.08.006","article-title":"Endothelial dysfunction \u2014 a major mediator of diabetic vascular disease","volume":"1832","author":"Sena","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"March (2)","key":"10.1016\/j.phrs.2021.105446_bib0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1468-1293.2005.00273.x","article-title":"Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort","volume":"6","author":"El-Sadr","year":"2005","journal-title":"HIV Med."},{"issue":"November (11)","key":"10.1016\/j.phrs.2021.105446_bib0220","article-title":"Metabolic risk factors in young adults infected with HIV since childhood compared with the general population","volume":"13","author":"Arrive","year":"2018","journal-title":"PLoS One"},{"issue":"December","key":"10.1016\/j.phrs.2021.105446_bib0225","article-title":"Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients","author":"Satta","year":"2017","journal-title":"J. Infect."},{"issue":"June (6)","key":"10.1016\/j.phrs.2021.105446_bib0230","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/jac\/dkv494","article-title":"Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients","volume":"71","author":"Calza","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"December (49)","key":"10.1016\/j.phrs.2021.105446_bib0235","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"February (1)","key":"10.1016\/j.phrs.2021.105446_bib0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","article-title":"Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial","volume":"16","author":"Nicholls","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"January","key":"10.1016\/j.phrs.2021.105446_bib0245","article-title":"Evacetrapib: another CETP inhibitor for dyslipidemia with No clinical benefit","volume":"1","author":"Eyvazian","year":"2017","journal-title":"Cardiol. Rev."},{"issue":"May (5)","key":"10.1016\/j.phrs.2021.105446_bib0250","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.02294-12","article-title":"Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state","volume":"57","author":"Fan-Havard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"December (12)","key":"10.1016\/j.phrs.2021.105446_bib0255","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"February (2)","key":"10.1016\/j.phrs.2021.105446_bib0260","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.107.129650","article-title":"Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice","volume":"324","author":"Alnouti Y, Klaassen CD","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"September (3)","key":"10.1016\/j.phrs.2021.105446_bib0265","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.112.194803","article-title":"Hormonal and chemical regulation of paraoxonases in mice","volume":"342","author":"Cheng","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"October (10)","key":"10.1016\/j.phrs.2021.105446_bib0270","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1194\/jlr.M800082-JLR200","article-title":"Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin","volume":"49","author":"Jaichander","year":"2008","journal-title":"J. Lipid Res."},{"issue":"May","key":"10.1016\/j.phrs.2021.105446_bib0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbi.2015.03.024","article-title":"Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats","volume":"233","author":"Pinheiro","year":"2015","journal-title":"Chem. Biol. Interact."},{"issue":"October (2)","key":"10.1016\/j.phrs.2021.105446_bib0280","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfl050","article-title":"Tissue distribution and ontogeny of sulfotransferase enzymes in mice","volume":"93","author":"Alnouti","year":"2006","journal-title":"Toxicol. Sci."},{"issue":"June (2)","key":"10.1016\/j.phrs.2021.105446_bib0285","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.atherosclerosis.2008.09.016","article-title":"Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice","volume":"204","author":"Tohyama","year":"2009","journal-title":"Atherosclerosis"},{"issue":"March (9)","key":"10.1016\/j.phrs.2021.105446_bib0290","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1074\/jbc.M112.410092","article-title":"Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion","volume":"288","author":"Miles","year":"2013","journal-title":"J. Biol. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:21:46Z","timestamp":1760912506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"alternative-id":["S1043661821000293"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105446","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105446"}}